FC Gamma Receptor IIIA

FC Gamma Receptor IIIA

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FC Gamma Receptor IIIA</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>FCGR3A</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08637" target="_blank">P08637</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1T89" target="_blank">1T89</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>29 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane (immune cells)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Ig superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Neuroinflammation</td>
</tr>
</table>

FC Gamma Receptor IIIA

Overview

FC Gamma Receptor IIIA is a protein encoded by the FCGR3A gene. It belongs to the Ig superfamily family and has a molecular weight of approximately 29 kDa. This protein is localized to Cell membrane (immune cells) and plays a significant role in the pathogenesis of [Alzheimer's Disease](/diseases/alzheimers-disease), Neuroinflammation.

Structure

FC Gamma Receptor IIIA has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: [1T89](https://www.rcsb.org/structure/1T89).

FC Gamma Receptor IIIA

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">FC Gamma Receptor IIIA</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>FCGR3A</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/P08637" target="_blank">P08637</a></td>
</tr>
<tr>
<td class="label">PDB</td>
<td><a href="https://www.rcsb.org/structure/1T89" target="_blank">1T89</a></td>
</tr>
<tr>
<td class="label">Mol. Weight</td>
<td>29 kDa</td>
</tr>
<tr>
<td class="label">Localization</td>
<td>Cell membrane (immune cells)</td>
</tr>
<tr>
<td class="label">Family</td>
<td>Ig superfamily</td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers), Neuroinflammation</td>
</tr>
</table>

FC Gamma Receptor IIIA

Overview

FC Gamma Receptor IIIA is a protein encoded by the FCGR3A gene. It belongs to the Ig superfamily family and has a molecular weight of approximately 29 kDa. This protein is localized to Cell membrane (immune cells) and plays a significant role in the pathogenesis of [Alzheimer's Disease](/diseases/alzheimers-disease), Neuroinflammation.

Structure

FC Gamma Receptor IIIA has been characterized structurally through X-ray crystallography and cryo-EM. Available PDB structures include: [1T89](https://www.rcsb.org/structure/1T89).

The protein's three-dimensional structure can also be explored via the [AlphaFold Protein Structure Database](https://alphafold.ebi.ac.uk/entry/P08637).

Normal Function

Under physiological conditions, FC Gamma Receptor IIIA performs essential functions in the nervous system. It is primarily found in Cell membrane (immune cells) and contributes to normal cellular homeostasis, signaling, and neuronal function.

Role in Disease

FC Gamma Receptor IIIA is implicated in the following neurodegenerative conditions:

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Neuroinflammation](/mechanisms/neuroinflammation)

Therapeutic Targeting

FC Gamma Receptor IIIA represents an important therapeutic target. Multiple drug development programs are exploring strategies to modulate its function, reduce toxic forms, or enhance clearance mechanisms.

Key Publications

External Links

• UniProt: [https://www.uniprot.org/uniprot/P08637](https://www.uniprot.org/uniprot/P08637)
• AlphaFold: [FC Gamma Receptor IIIA](https://alphafold.ebi.ac.uk/entry/P08637)
• PDB: [1T89](https://www.rcsb.org/structure/1T89)

Receptor Biology

Expression Pattern

FCGR3A is expressed primarily on:

• Natural Killer (NK) cells: Highest expression, enables antibody-dependent cellular cytotoxicity (ADCC)[@wang2015]
• Macrophages: Medium to high expression, medites phagocytosis
• Neutrophils: Lower expression, FCGR3B is predominant
• Dendritic cells: Subset expression

• Perivascular macrophages: Monitor CNS entry of immune complexes
• Infiltrating NK cells: In inflammatory conditions
• Activated microglia: Induction under IFN-γ priming

Ligand Binding

FCGR3A binds IgG immune complexes with low-to-moderate affinity[@clynes2007]:

• IgG1: Highest affinity, primary ligand
• IgG3: Moderate affinity
• IgG4: Lower affinity

Function in Immunity

Antibody-Dependent Cellular Cytotoxicity (ADCC)

FCGR3A is the primary mediator of ADCC, a key effector mechanism for therapeutic antibodies[@clynes2007]:

This mechanism underlies antibody therapies for cancer and is relevant to antibody-based AD therapeutics.

Phagocytosis

On macrophages, FCGR3A mediates:

• Immune complex clearance
• Antibody-opsonized pathogen killing
• Antigen presentation

Cytokine Release

FCGR3A cross-linking triggers:

• IFN-γ secretion
• TNF-α release
• Chemokine production

FCGR3A in Neuroinflammation

CNS Immune Surveillance

Perivascular macrophages express FCGR3A and monitor the CNS for circulating immune complexes[@selvaraj2018]. Their functions include:

• Clearing antibody complexes that enter the CNS
• Signaling when harmful immune complexes are detected
• Recruiting additional immune cells if needed

NK Cell Infiltration

NK cells can infiltrate the CNS in neurodegenerative conditions:

• Increased in AD and MS brain tissue
• May contribute to cytotoxic damage
• Interact with FCGR3A for target recognition

Therapeutic Antibodies

Therapeutic monoclonal antibodies engage FCGR3A on peripheral immune cells[@taylor2015]:

• Aducanumab: Engages FCGR3A on macrophages
• Lecanemab: Less FCGR3A engagement
• Donanemab: Intermediate engagement

Antibody-Dependent Cellular Cytotoxicity in Detail

ADCC Mechanism

Antibody-dependent cellular cytotoxicity (ADCC) is a key effector mechanism of therapeutic antibodies[@clynes2007]. The process unfolds as follows:

1. Target Recognition
Therapeutic antibody binds to antigen on target cell surface. The antibody is typically IgG1 isotype for optimal FCGR3A engagement.

2. Fc Region Display
The antibody Fc region is now positioned for Fc receptor recognition. FCGR3A on effector cell (NK cell) binds to this Fc region.

3. Effector Cell Activation
Cross-linking of multiple FCGR3A receptors triggers ITAM signaling:

• Src family kinases phosphorylate ITAM motifs
• Syk family kinases are recruited
• Downstream cascades activate

• Perforin forms pores in target cell membrane
• Granzyme enters via pores
• Granzyme triggers apoptosis

• Caspase activation
• DNA fragmentation
• Membrane blebbing

NK Cell Development and FCGR3A

NK Cell Maturation
FCGR3A expression increases during NK cell maturation:

• Stage 1 (CD34+): FCGR3A-negative
• Stage 2 (CD34+CD161+): Low FCGR3A
• Stage 3 (CD56+): Moderate FCGR3A
• Stage 4 (CD56+CD16high): High FCGR3A - the primary ADCC-mediating population

• Peripheral blood NK cells: High FCGR3A
• Uterine NK cells: Low FCGR3A
• Liver NK (pit cells): Variable FCGR3A

Therapeutic Implications for AD

Antibody Effector Functions

In Alzheimer's disease, therapeutic antibodies engage FCGR3A through multiple mechanisms[@taylor2015]:

Amyloid Clearance Pathways:

Amyloid-Related Imaging Abnormalities (ARIA)

ARIA is a major safety concern for AD antibodies:

• ARIA-E: Edema (vasogenic)
• ARIA-H: Hemorrhage (microhemorrhages)

• Antibody recruits peripheral immune cells
• Immune complex deposition in vessels
• Localized inflammation

Clinical Considerations

Aducanumab (Aduhelm):

• Fully human IgG1
• Strong FCGR3A engagement
• ARIA rate ~35%

• Humanized IgG1
• Moderate FCGR3A engagement
• ARIA rate ~12%

• Humanized IgG1
• Intermediate FCGR3A
• ARIA rate ~17%

Fc Receptor Polymorphisms

FCGR3A Polymorphisms

Several FCGR3A polymorphisms affect receptor function[@liu2016]:

V158F (rs396991)
A common polymorphism affecting:

• V158 (higher affinity): Better IgG1 binding, enhanced ADCC
• F158 (lower affinity): Reduced IgG1 binding

• FCGR3B expression
• Immune complex clearance

• V158 patients show better antibody efficacy
• F158 patients may need higher doses

NK Cells in Neurodegeneration

NK Cell CNS Infiltration

NK cells can infiltrate the CNS in neurodegenerative conditions[@selvaraj2018]:

Mechanisms of Entry:

• Chemokine receptor-mediated recruitment
• Compromised blood-brain barrier
• Adhesion molecule expression

• Perivascular clustering
• Parenchymal infiltration
• Association with amyloid plaques

NK Cell Functions in CNS

Cytotoxic Activity
NK cells can directly kill target cells:

• NKG2D-mediated recognition
• Perforin/granzyme release
• Expressing TNF-related apoptosis

• IFN-γ: T-cell activation
• TNF-α: Inflammation
• IL-17: neutrophil recruitment

• Dendritic cell maturation
• T-cell polarization
• Microglial activation

NK Cells in AD

Reduced NK Function
AD is associated with:

• Decreased NK cell numbers
• Impaired cytotoxicity
• Altered cytokine profiles

• Cytokine-based therapies
• Adoptive NK cell transfer
• FCGR3A activation

Clinical Development

Biomarker Potential

NK Cell Biomarkers in AD:

• NK cell count in CSF
• FCGR3A expression level
• Cytokine production capacity
• Cytotoxic activity assays

• Serial NK cell monitoring
• Therapy response markers

Therapeutic Targeting

NK Cell-Enhancing Therapies:

• IL-2 and IL-15 to expand NK cells
• FCGR3A-activating antibodies
• NK cell engagers

• NK cell therapy with anti-Aβ antibodies
• Enhanced amyloid clearance

Summary

FCGR3A (CD16) is a low-affinity Fcγ receptor for IgG that mediates ADCC, phagocytosis, and cytokine release. As the primary receptor for NK cell effector functions, FCGR3A plays crucial roles in both cancer antibody therapy and potentially in AD antibody therapeutics. Understanding FCGR3A function is essential for developing effective immunotherapies for neurodegenerative diseases.

Structural Biology

Extracellular Domain Architecture

The extracellular region of FCGR3A contains two immunoglobulin-like domains that form the ligand-binding site for IgG Fc regions[@pdb]. Unlike FCGR2A, FCGR3A exists as a homodimer on the cell surface:

• D1 domain: Membrane-proximal Ig-like domain
• D2 domain: Membrane-distal ligand-binding domain
• Dimer interface: Critical for high-affinity IgG binding

Transmembrane Region

FCGR3A contains a transmembrane domain that differs between isoforms:

• Membrane-bound form: FcGR3A-158V/F (transmembraneanchored)
• GPI-anchored form: FCGR3B (neutrophil-specific)

Signaling Motifs

FCGR3A signaling proceeds through associated ITAM-bearing subunits:

• FcR γ-chain: Primary signaling subunit
• CD3ζ chain: Alternative in some NK cells
• Syk family kinases: Downstream effectors

Functional Mechanisms

ADCC Effector Mechanisms

The molecular mechanisms of ADCC involve coordinated signaling events:

Cytotoxic Granule Pathway

NK cells use specialized cytotoxic granules:

• Perforin: Pore-forming protein (67 kDa)
• Granzymes: Serine proteases (Granzymes A, B, K)
• Granulysin: Antimicrobial and pro-apoptotic

Fc Receptor Collaboration

Multiple Fcγ receptors cooperate in immune responses:

• FCGR3A: Primary ADCC receptor on NK cells
• FCGR2A: Phagocytosis on macrophages
• FCGR1: High-affinity receptor, antigen presentation

NK Cell Biology

NK Cell Subsets

Human NK cells are divided into subsets with different FCGR3A:

| Subset | Markers | FCGR3A | Function |
|--------|---------|--------|----------|
| CD56brightCD16- | High CD56 | Low | Cytokine production |
| CD56dimCD16+ | Low CD56 | High | Cytotoxicity (ADCC) |
| CD56-CD16+ | Adaptive NK | Variable | Memory-like |

NK Cell Activation

FCGR3A signaling integrates with other NK cell activation receptors:

• Activating receptors: NKG2D, NCRs (NKp46, NKp44, NKp30)
• Inhibitory receptors: KIRs, NKG2A
• Integration: Activating vs. inhibitory signal balance

Tissue Distribution

NK cells populate different anatomical compartments:

• Peripheral blood: ~90% CD56dimCD16+
• Lymph nodes: Mixed populations
• Uterus: ~70% CD56brightCD16-
• Brain: Low numbers, infiltration in disease

Clinical Relevance

Therapeutic Antibody Engineering

Modern antibody engineering optimizes FCGR3A interactions:

Enhancing FCGR3A engagement:

• IgG1 isotype (not IgG2 or IgG4)
• Fc region mutations (G298A, S298A)
• Glycoengineering (non-fucosylated)

• IgG2 or IgG4 isotype
• L234A, L235A mutations
• Glycosylation modifications

FCGR3A in Cancer Therapy

FCGR3A is crucial for cancer antibody therapeutics:

Approved FCGR3A-engaging antibodies:

• Rituximab (anti-CD20)
• Trastuzumab (anti-HER2)
• Cetuximab (anti-EGFR)
• Daratumumab (anti-CD38)

• FCGR3A V158 correlates with response
• Polymorphisms affect outcomes

FCGR3A in Autoimmunity

Dysregulated FCGR3A contributes to autoimmunity:

• Autoantibody-mediated damage: ITP, AIHA
• Immune complex clearance: Lupus, vasculitis
• Therapeutic targeting: FcRn, corticosteroids

Neuroimmunology

Blood-Brain Barrier Interactions

FCGR3A+ immune cells interact with the BBB:

• Perivascular macrophages: Monitor CNS
• NK cell trafficking: Under inflammatory conditions
• BBB modulation: Cytokine effects on barrier

CNS Immune Privilege

The CNS has specialized immune surveillance:

• Meningeal lymphatics: Drain immune complexes
• Glymphatic system: Clearance pathways
• Microglial interactions: With peripheral immune cells

Neurodegenerative Disease Context

FCGR3A contributes to neurodegenerative disease immunopathology:

Alzheimer's Disease:

• Peripheral immune cell recruitment
• Amyloid clearance via ADCC
• ARIA risk factor

• α-Synuclein antibody responses
• NK cell dysfunction
• Inflammatory cascades

• Antibody-mediated demyelination
• NK cell surveillance
• Therapeutic antibody responses

Research Methods

Detection Techniques

Flow cytometry:

• Anti-FCGR3A antibodies (e.g., 3G8, B73.1)
• Intracellular staining for activation markers
• Functional assays (calcium flux, degranulation)

• Brain tissue FCGR3A localization
• Colocalization with immune cell markers
• Quantification of infiltrating cells

Functional Assays

ADCC assays:

• Chromium release (51Cr)
• Flow-based killing assays
• Real-time imaging (Incucyte)

• ELISA for IFN-γ, TNF-α
• Intracellular cytokine staining
• Multiplex bead arrays

Future Directions

Emerging Therapies

NK cell engagers:

• Bispecific antibodies targeting FCGR3A
• Tri-specific killer engagers
• Enhanced tumor killing

• FCGR3A as target
• Enhanced persistence
• Cytokine engineering

Biomarker Development

Patient stratification:

• FCGR3A V158F genotyping
• NK cell phenotyping
• Therapeutic antibody response prediction

• FCGR3A expression as activity marker
• NK cell functional assays
• Imaging of immune cell infiltration

Evolutionary Perspectives

Phylogenetic Distribution

FCGR3A and related receptors show distinct evolutionary patterns:

• Primates: Full-length FCGR3A with signaling subunits
• Rodents: Different FcγR repertoire, FCGR3 orthologs
• Lower mammals: Simplified receptor systems
• Non-mammalian: Fc receptor-like proteins

Species-Specific Considerations

Preclinical translation requires understanding species differences:

• Murine FCGR3: Different affinity profiles
• Non-human primates: Closest to human FCGR3A
• Engineered models: Humanized mouse models

Conclusion

FCGR3A represents a critical receptor linking humoral immunity to cellular effector functions. Its role in ADCC makes it essential for therapeutic antibody efficacy, while also contributing to neuroinflammatory processes in neurodegenerative diseases. Understanding FCGR3A biology informs both antibody engineering and clinical use in AD and related conditions.

Cross-links

• [FCGR3A Gene](/genes/fcgr3a)
• [FCGR2A Protein](/proteins/fcgr2a-protein)
• [Natural Killer Cells](/cell-types/natural-killer-cells)
• [Neuroinflammation](/mechanisms/neuroinflammation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Antibody Therapy](/mechanisms/antibody-therapy)

See Also

• [Proteins Index](/proteins)
• [Genes Index](/genes)
• [Diseases Index](/diseases)
• [Mechanisms Index](/mechanisms)
• [Immunology Index](/mechanisms/immunology)

References